Fishawack Group Acquires Healthcircle to Strengthen Creative Offering
10.7.2018 09:30:00 EEST | Business Wire | Press release
The Fishawack Group of Companies, one of the world’s largest independent medical communications organisations, has acquired Healthcircle Advertising Limited, a strategic brand communications agency with offices in London and Portugal.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180709005905/en/
Top row: Dominic Miller, Fishawack COO, Gail Flockhart, Fishawack Managing Partner, Liz Maclaren, Healthcircle Creative Director, Dr. David Ingram, Healthcircle Managing Partner; Bottom row: Mike Taylor, Healthcircle Managing Director, Oliver Dennis, Fishawack CEO (Photo: Business Wire)
“This acquisition is a major step in Fishawack’s plan to build a global strategic creative agency that can work alongside our medical communications business,” explained Oliver Dennis, Chief Executive Officer of the Fishawack Group. “We also acquired US-based Carling Communications in July last year. Carling needed critical mass in Europe and Healthcircle needed a US partner. This is a great match and positions us to deliver integrated creative and medcomms solutions for clients on a truly global scale.”
Mike Taylor, Managing Director of Healthcircle added, “We’ve been on the lookout for a partner to support our growth in the US whilst also providing us access to scientific and strategic talent. Healthcircle and Fishawack have already collaborated extensively and we’ve known and worked with many of the Carling team over our years in the business.”
Gail Flockhart, Group Managing Director at Fishawack said, “All agencies are collections of people with different talents. What makes us different is the investment we make in establishing real chemistry between teams so that collaboration is fun and triggers new ideas. We’re still at a size where we can make this meaningful.”
About the Fishawack Group
The Fishawack Group of Companies is one of the largest independent medical communications specialists, with offices in the UK (Knutsford, Oxford, and Brighton), the USA (Philadelphia, PA, and San Diego, CA), Switzerland (Basel), and India (Hyderabad).
For over 17 years, Fishawack has been partnering with global and regional pharmaceutical, biotechnology, and medical device clients to develop and deliver services in the fields of medical communications, scientific engagement, market access, strategic consultancy, and thought leader consultancy. For more detailed information about our services, please see the Fishawack Group website at www.fishawack.com.
We have built our reputation on excellence, creativity, and transparency.
About Healthcircle
Healthcircle is a full-service strategic brand communications agency. With extensive experience in direct-to-patient communications, creative digital solutions and creative medcomms, Healthcircle has consistently won awards for its surprising and innovative creative work. Healthcircle is headquartered in London, UK, with an office in Cascais, Portugal.
Healthcircle strongly believes that connecting strategy and creative is the key to brand success and has demonstrated the success of this approach on some of the largest brands in the global pharmaceutical marketplace during the last 10 years. More information is available at www.healthcircle-uk.com
Fishawack Group of Companies
www.fishawack.com
Twitter:
@Fishawack
LinkedIn:
Fishawack Group of Companies
Headquarters:
100–102 King Street, Knutsford, Cheshire, WA16 6HQ, UK
Tel: +44
1565 756600
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180709005905/en/
Contact information
The Fishawack Group
Gail Flockhart
Group
Managing Director
gail.flockhart@fishawack.com
or
Healthcircle
Advertising Ltd
Mike Taylor
Managing Director
Mike.taylor@Healthcircle-uk.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Presents New Data on ALYFTREK ® at European Cystic Fibrosis Conference5.6.2026 19:00:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data demonstrating the potentially transformative impact of treating cystic fibrosis (CF) with ALYFTREK ® (vanzacaftor/tezacaftor/deutivacaftor) in children ages 2 to 5, as well as data from 96-week interim analyses of two open-label extension studies of ALYFTREK in children 6 to 11 years and people 12 years and older demonstrating the long-term safety and efficacy profile of the medicine. The data, presented at the European Cystic Fibrosis Conference, show children ages 2 to 5 with vanzacaftor/tezacaftor/deutivacaftor-responsive genotypes including those who are homozygous for the F508del mutation (F/F) and those who have F508del/minimal function mutations (F/MF)on ALYFTREK had further improvement in CFTR function from a TRIKAFTA ® baseline as measured by sweat chloride (SwCl), with 65% having achieved SwCl <30 mmol/L after treatment with ALYFTREK. Vertex also presented Phase 3 data of children ages 1 to <2 with TRIKAF
Owkin to Build AI Agents as Part of a Multi-Year K Pro Collaboration with Sanofi5.6.2026 14:00:00 EEST | Press release
Owkin, the agentic AI company pioneering Biological Artificial Superintelligence to transform drug discovery and development, today announced a multi-year collaboration with Sanofi to co-develop next-generation biopharma agents, to be backed by a five-year license for K Pro, Owkin’s AI Scientist. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260605704506/en/ K Pro, Owkin's AI scientist for biology, powered by multimodal patient data for smarter biopharma decision making. Owkin and Sanofi have collaborated since 2021 through a €90 million strategic partnership focused on target identification in oncology and patient subgrouping. The collaboration was later expanded to include drug positioning for Sanofi’s immunology pipeline. This new collaboration represents the next evolution in the partnership. During the five-year collaboration, Owkin will lead the end-to-end development of novel AI-driven biopharma agents purpose-built
DFNS Rebrands as the Core Banking Platform for Digital Assets5.6.2026 13:41:00 EEST | Press release
DFNS today announced a rebrand, marking its evolution from a wallet infrastructure to the first core banking platform for digital assets. The company is introducing a new logo, website, and market position as fintechs and institutions move their products and operations onchain. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260603859127/en/ Banks, fintechs, asset managers, trading firms, payment providers, market infrastructures, and clearing houses have stopped asking how to "add crypto." They're asking how to run financial products, controls, workflows, and client services on blockchain rails, with the reliability expected of core infrastructure. Some are going further still, exploring whether the blockchain can serve as the ledger itself, where an account is an onchain object rather than a row in a database. Where IBANs, virtual accounts, and blockchain wallets converge into one governed financial account. “DFNS was built
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.6.2026 13:30:00 EEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to seventeen newly hired non-executive employees. The equity awards were granted on June 1, 2026 and consisted of options to purchase an aggregate of 157,000 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 74,700 shares. The options have an exercise price per share equal to $14.19, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restrict
Renewable Electricity, Soft Wheat Flour From Regenerative Agriculture, Initiatives to Support Local Communities: Barilla Shares These and Other Projects in “Stories of Sustainability.”5.6.2026 11:00:00 EEST | Press release
A slimmer Tagliatelle pack that saves 150 tons of cardboard and cuts transport-related CO₂ emissions by 20%1; ready-made sauce jars made with around 65% recycled glass; the progressive scaling of regenerative agriculture practices across Barilla’s value chain and initiatives supporting inclusion and equal opportunities across the Group’s production sites and communities. These are just some of the “sustainability” stories the Barilla Group is sharing on World Environment Day with the publication of its 2025 Sustainability Report. The report comes just after Barilla was named the world’s most reputable company in the food sector for the third year running and, for the first time, ranked among the global top 10 in the Global RepTrak 100 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260603162436/en/ “The future of the planet will increasingly depend on our ability to spread culture and education,” says Paolo Barilla, Vic
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom